SG Trading Solutions LLC Invests $4.78 Million in Merck & Co., Inc. $MRK

SG Trading Solutions LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, Holdings Channel reports. The fund purchased 45,373 shares of the company’s stock, valued at approximately $4,776,000. Merck & Co., Inc. makes up about 1.1% of SG Trading Solutions LLC’s holdings, making the stock its 16th largest position.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares during the last quarter. State Street Corp lifted its stake in Merck & Co., Inc. by 1.6% in the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock valued at $12,737,504,000 after purchasing an additional 1,859,990 shares during the last quarter. Wellington Management Group LLP grew its holdings in Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares during the period. Geode Capital Management LLC grew its holdings in Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after purchasing an additional 249,110 shares during the period. Finally, DLD Asset Management LP increased its position in Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on MRK shares. UBS Group boosted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. JPMorgan Chase & Co. lifted their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Wells Fargo & Company dropped their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Trading Down 1.2%

NYSE:MRK opened at $114.04 on Friday. The company has a market cap of $281.65 billion, a P/E ratio of 32.12, a P/E/G ratio of 2.60 and a beta of 0.21. The stock’s fifty day moving average price is $116.12 and its two-hundred day moving average price is $113.60. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $125.14. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be paid a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.